Recruiting
T-cell type acute leukaemia+1
RecruitingInvestigationalNo placebo
Long-term Follow-up Study for Patients with Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma Treated with OC-1 Cells
InvestigationalNo placebo
- Disease:T-cell type acute leukaemiaPrecursor T-lymphoblastic lymphoma/leukaemia recurrent
- Substances:Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
Countries:
Spain
Spain- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Autologous T-Cells Ex Vivo Modified With A Lentiviral Vector Encoding A Chimeric Antigen Receptor Specific For Cd1A
- Sponsor:Onechain Immunotherapeutics S.L.
